| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/26/2000 | EP0973926A1 Adenoviral vectors with modified tropism |
| 01/26/2000 | EP0973925A2 Matrix derived anti-hiv peptides and transdominant proteins |
| 01/26/2000 | EP0973916A1 Composition and method for inducing an immune response against tumour-related antigens |
| 01/26/2000 | EP0973914A1 Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use |
| 01/26/2000 | EP0973904A1 COMPOSITIONS AND USE OF M-CSF-alpha |
| 01/26/2000 | EP0973903A2 Protein for inhibiting apoptosis |
| 01/26/2000 | EP0973902A1 Radioisotope concentrator methods and compositions |
| 01/26/2000 | EP0973900A1 flt3 LIGAND CHIMERIC PROTEINS |
| 01/26/2000 | EP0973895A1 Transcription factor islet-brain 1 (ib1) |
| 01/26/2000 | EP0973894A1 Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 01/26/2000 | EP0973892A2 28 human secreted proteins |
| 01/26/2000 | EP0973890A2 Secreted proteins and polynucleotides encoding them |
| 01/26/2000 | EP0973888A1 Dendritic cell-derived growth factor |
| 01/26/2000 | EP0973881A2 Mycobacterium recombinant vaccines |
| 01/26/2000 | EP0973879A2 Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
| 01/26/2000 | EP0973803A1 Peptides useful for reducing symptoms of toxic shock syndrome |
| 01/26/2000 | EP0973794A1 Netrin receptors |
| 01/26/2000 | EP0973575A1 Gene therapeutic treatment of blood vessel associated disorders |
| 01/26/2000 | EP0973539A2 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 01/26/2000 | EP0973538A1 Modified proteins which bind extracellular matrix components |
| 01/26/2000 | EP0973394A1 NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO $i(HELICOBACTER PYLORI) AND VACCINE COMPOSITIONS THEREOF |
| 01/26/2000 | EP0973381A2 Animal model for evaluation of vaccines |
| 01/26/2000 | CN1048731C Polynucleotide of drug binding protein as coded CSAID |
| 01/25/2000 | US6018042 An oligonucleotide derivative capable of modulating the biosynthesis of human s-adenosylmethionine decarboxylase enzyme; antiproliferative/antitumor/antimetastasis agents |
| 01/25/2000 | US6018025 Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target |
| 01/25/2000 | US6017898 Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor |
| 01/25/2000 | US6017763 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 01/25/2000 | US6017761 Isolating nucleic acid sequence encoding a minimal open reading frame and inserting into a plasmid, then transformed into eukaryotic cells that are free of endogenous retroviral nucleic acid, producing recombinant retroviral cells |
| 01/25/2000 | US6017759 Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon |
| 01/25/2000 | US6017727 Syndecan enhancer element and syndecan stimulation of cellular differentiation |
| 01/25/2000 | US6017716 Mixing biological sample with an isolated protein and determining binding of antibodies in sample to protein; antibody binding idicates melanoma |
| 01/25/2000 | US6017705 Nucleic acid molecules that codes for tumor rejection antigens; diagnosis and screening for possible presence of lymphoma, or head and neck squamous cell carcinoma, skin and mammary carcinomas |
| 01/25/2000 | US6017524 Inhibiting the growth p53 deficient tumor cells by administering the p53 gene |
| 01/20/2000 | WO2000003248A1 Method for identifying a presenilinase inhibitor |
| 01/20/2000 | WO2000003027A1 Method for improving the gene transfer of genetic material in mammalian cells through the use of p21 (waf-1) |
| 01/20/2000 | WO2000003014A1 Pharmaceutical uses of nab1 and nab2 |
| 01/20/2000 | WO2000003004A2 Presenilin 2 specific ribozyme |
| 01/20/2000 | WO2000003001A1 Liver stem cell |
| 01/20/2000 | WO2000002950A1 Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
| 01/20/2000 | WO2000002912A2 Disintegrin homologs |
| 01/20/2000 | WO2000002911A2 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/20/2000 | WO2000002909A2 Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 01/20/2000 | WO2000002908A2 Inhibition of alopecia |
| 01/20/2000 | WO2000002897A2 Delta cleavage products and methods based thereon |
| 01/20/2000 | WO2000002860A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | WO2000002591A1 Polynucleotide vaccine formulations |
| 01/20/2000 | WO2000002590A1 Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
| 01/20/2000 | WO2000002589A1 Modulation of haemopoietic cell activity and agents useful for same |
| 01/20/2000 | WO2000002588A1 Targeted site specific drug delivery compositions and method of use |
| 01/20/2000 | WO2000002577A1 Therapeutic use of uncoupling protein hhfcw60 |
| 01/20/2000 | WO2000002520A2 T-lymphocyte exchange |
| 01/20/2000 | WO1999060117A3 Prax-1 polypeptide |
| 01/20/2000 | WO1999058560A3 Prostapin gene and protein and uses thereof |
| 01/20/2000 | WO1999058559A3 Factors affecting tumor necrosis factor receptor releasing enzyme activity |
| 01/20/2000 | WO1999057273A3 Cytoplasmic antiproteinase-3 coding sequence in gene therapy |
| 01/20/2000 | WO1999053943A3 Therapeutic angiogenic factors and methods for their use |
| 01/20/2000 | WO1999053052A3 Srebp-2-deficient cell lines |
| 01/20/2000 | WO1999048916A3 Hypoxia-inducible human genes, proteins, and uses thereof |
| 01/20/2000 | WO1999047674A3 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/20/2000 | WO1999047150A3 A pharmaceutical composition containing ezrin mutated on tyrosine 353 |
| 01/20/2000 | WO1999042091A3 Use of polycations as endosomolytic agents |
| 01/20/2000 | WO1999038964A3 Promoter regions of the mouse and human telomerase rna component genes |
| 01/20/2000 | CA2337680A1 Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
| 01/20/2000 | CA2337258A1 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | CA2336992A1 Polynucleotide vaccine formulations |
| 01/20/2000 | CA2336958A1 Liver stem cell |
| 01/20/2000 | CA2336805A1 Pharmaceutical uses of nab1 and nab2 |
| 01/20/2000 | CA2334168A1 Inhibition of alopecia |
| 01/20/2000 | CA2333893A1 Delta cleavage products and methods based thereon |
| 01/20/2000 | CA2333855A1 Isolated amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins |
| 01/20/2000 | CA2332625A1 Interaction of human beta amyloid precursor protein (.beta.-app) with human lon-protease like protein (hslon) |
| 01/20/2000 | CA2332497A1 Presenilin 2 specific ribozyme |
| 01/20/2000 | CA2332344A1 Method for identifying a presenilinase inhibitor |
| 01/20/2000 | CA2332311A1 Disintegrin homologs |
| 01/19/2000 | EP0972841A1 Display of viral proteins as ligands for cell-surface receptor |
| 01/19/2000 | EP0972837A2 Ubiquitin specific protease like protein |
| 01/19/2000 | EP0972831A1 Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer |
| 01/19/2000 | EP0972779A2 Oligonucleotide-polyamide conjugates |
| 01/19/2000 | EP0972523A2 Method and compositions for inducing immunity to viruses |
| 01/19/2000 | EP0972518A2 Exchange of T lymphocytes |
| 01/19/2000 | EP0972200A1 Screening and treatment using complement regulator or receptor proteins |
| 01/19/2000 | EP0972064A1 Methods for producing retroviral vectors with an altered tropism |
| 01/19/2000 | EP0972063A2 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| 01/19/2000 | EP0972054A1 Enhancement of immune response using targeting molecules |
| 01/19/2000 | EP0972050A1 Csk homologons kinaze (chk) for detecting and treating breast cancer |
| 01/19/2000 | EP0972044A1 Chemokine beta-6 |
| 01/19/2000 | EP0972037A2 $g(b)-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER |
| 01/19/2000 | EP0972036A2 Prion propagation inhibition by dominant-negative prion protein mutants |
| 01/19/2000 | EP0972033A1 Modulators of the function of receptors of the tnf/ngf receptor family |
| 01/19/2000 | EP0972031A1 Procollagen assembly |
| 01/19/2000 | EP0972028A1 Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
| 01/19/2000 | EP0972024A1 A tumor suppressor designated ts10q23.3 |
| 01/19/2000 | EP0972022A2 Polynucleotides and polypeptides encoding receptors |
| 01/19/2000 | EP0972021A1 Extracellular/epidermal growth factor like protein |
| 01/19/2000 | EP0972019A1 Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer |
| 01/19/2000 | EP0972017A1 Efficient nuclear transfer using fetal fibroblasts |
| 01/19/2000 | EP0972015A1 Enzyme having s-adenosyl-l-homocysteine hydrolase (ahcy) type activity |
| 01/19/2000 | EP0971952A2 Diagnosis method and reagents |
| 01/19/2000 | EP0971950A2 Secreted proteins and polynucleotides encoding them |
| 01/19/2000 | EP0971736A1 Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |